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Abstract
Objectives To examine the impact of use of rapid diagnostic tests for
malaria on prescribing of antimicrobials, specifically antibiotics, for acute
febrile illness in Africa and Asia.
Design Analysisof nine preselected linked and codesigned observational
and randomised studies (eight cluster or individually randomised trials
and one observational study).
Setting Public and private healthcare settings, 2007-13, in Afghanistan,
Cameroon, Ghana, Nigeria, Tanzania, and Uganda.
Participants 522 480 children and adults with acute febrile illness.
Interventions Rapid diagnostic tests for malaria.
Main outcomemeasures Proportions of patients for whom an antibiotic
was prescribed in trial groups who had undergone rapid diagnostic testing
compared with controls and in patients with negative test results
compared with patients with positive results. A secondary aim compared
classes of antibiotics prescribed in different settings.
Results Antibiotics were prescribed to 127 052/238 797 (53%) patients
in control groups and 167 714/283 683 (59%) patients in intervention
groups. Antibiotics were prescribed to 40% (35 505/89 719) of patients
with a positive test result for malaria and to 69% (39 400/57 080) of
those with a negative result. All but one study showed a trend toward
more antibiotic prescribing in groups who underwent rapid diagnostic
tests. Random effects meta-analysis of the trials showed that the overall
risk of antibiotic prescription was 21% higher (95% confidence interval
7% to 36%) in intervention settings. In most intervention settings, patients
with negative test results received more antibiotic prescriptions than
patients with positive results for all the most commonly used classes:
penicillins, trimethoprim-sulfamethoxazole (one exception), tetracyclines,
and metronidazole.
Conclusions Introduction of rapid diagnostic tests for malaria to reduce
unnecessary use of antimalarials—a beneficial public health
outcome—could drive up untargeted use of antibiotics. That 69% of
patients were prescribed antibiotics when test results were negative
probably represents overprescription.This included antibiotics from
several classes, including those like metronidazole that are seldom
appropriate for febrile illness, across varied clinical, health system, and
epidemiological settings. It is often assumed that better disease specific
diagnostics will reduce antimicrobial overuse, but they might simply shift
it from one antimicrobial class to another. Current global implementation
of malaria testing might increase untargeted antibiotic use and must be
examined.
Introduction
There is wide recognition that overuse of antimicrobials drives
resistance in micro-organisms.1-4 Global concern is growing in
the face of accumulating evidence showing international and
intercontinental spread of bacterial resistance.2-5 Dealing this
crisis has become a major priority, with the World Health
Assembly adopting a global action plan in 2015.6 Several
strategies have been proposed to contain the risks of
antimicrobial resistance, including improved surveillance,
optimised use of available antibiotics, development of new
antibiotics, and development of better diagnostic tests. Tackling
antimicrobial resistance will require sustained cooperation across
international borders and agencies.7 8
Across tropical and subtropical zones in Africa and Asia, acute
febrile illness is one of the most common reasons for people to
seek treatment from health services.9 Historically, many if not
most fevers have been considered to result from malaria and
have been treated empirically with antimalarials.10 Many other
infectious and non-infectious diseases, however, can cause
similar symptoms, including bacterial and viral infections.
Management of fever has received considerable attention in
recent years, with widespread efforts, spearheaded by WHO,
to improve diagnosis of malaria and reduce untargeted use of
antimalarials.11 12 These efforts have relied heavily on
introduction of rapid diagnostic tests for malaria. These tests
detect parasite antigen in a fingerprick blood sample and are
seen as simple and quick to use compared with the traditional
diagnostic method of microscopy. Each year, millions of rapid
diagnostic tests are now used in diverse healthcare settings
across endemic areas.13 In many settings this has led to a
reduction in overprescription of antimalarials, but the impact
on use of other treatments is less clear.14 There are now calls to
expand disease specific rapid diagnostics as a solution to other
antimicrobial prescribing challenges.15
We hypothesised that improved malaria diagnosis to reduce use
of antimalarials, a widely used antimicrobial class, could
paradoxically drive an increase in untargeted use of other
antimicrobials, such as antibiotics, particularly when test results
for malaria are negative.16 Little is known about the causes of
non-malaria febrile illness in manymalaria endemic countries,17
where microbiological diagnostic facilities are limited or
non-existent in most settings. Health workers can resort only
to educated guesswork and empirical treatment for febrile
patients who do not have malaria. Improvements in malaria
diagnosis could simply reduce the overuse of antimalarials, or
divert overuse to other products like antipyretics, or it could
divert antimalarial overuse to other antimicrobials, particularly
antibiotics.18 Prescribing practices are not well documented or
regulated in regions with little healthcare infrastructure and with
relatively unrestricted access to antimicrobials.18-24 Similarly,
monitoring and surveillance of antimicrobial resistance is not
conducted in most lower and middle income countries, but
available data do show clinically relevant resistance in many
common bacterial pathogens.25-35
TheACTConsortium (www.actconsortium.org) included several
studies that evaluated the potential of rapid diagnostic tests for
malaria to improve case management for patients with
undifferentiated fever in malaria endemic areas. Data from these
studies, conducted in multiple geographical, epidemiological,
and health system settings, provide the largest and most varied
sample to date to assess whether changes in antimalarial
prescribing behaviour are associated with shifts in antibiotic
prescribing. To inform policy for treatment of febrile illness,
we compared settings where tests were and were not
implemented, examined the differences in antibiotic prescribing
overall and by test result, and identified the antibiotic classes
used in different settings.
Methods
Overview of studies included in analysis
The ACT Consortium conducted linked and co-designed
research studies in Africa and Asia, including multiple studies
designed to evaluate the impacts on healthcare of introducing
rapid diagnostic tests for malaria in various settings. The studies
were designed to be complementary and mutually reinforcing
and to cover a range of settings. These rapid diagnostic tests
were introduced in various epidemiological settings and health
service sectors (public, private retail, and community) and with
different approaches to implementation. To avoid selection bias,
our combined analysis includes all studies in the ACT
Consortium that were designed a priori to test the effect of
introduction of rapid diagnostic tests for malaria on prescribing
of antimalarial drugs, where providers could prescribe
antibiotics, and did not include any other studies post hoc.
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Detailed descriptions of the individual studies are available in
open access publications.36-43
We included in the analysis studies that met the following
criteria: evaluated an intervention to implement rapid diagnostic
tests for malaria in settings where participating providers could
prescribe both antimalarials and antibiotics, compared sites with
and without the intervention, documented prescriber behaviour
as a primary outcome, and collected individual patient data on
diagnostic test results and treatments prescribed including
antibiotics. Tables 1 and 2⇓ present descriptions of the nine
studies meeting these criteria. In all of the studies the prescribers
used rapid diagnostic tests for illness syndromes that clinically
could have been malaria.
The studies were conducted in 2007-13 in Afghanistan,
Cameroon, Ghana, Nigeria, Tanzania, and Uganda in a mix of
rural and urban settings. Rapid diagnostic tests were introduced
among government sponsored community health workers
(Afgh-com (T Leslie, et al, in preparation)), in public health
facilities only (Afgh-pub,36Cam-pub,37Ghan-pub,38Tanz1-pub,40
Tanz2-pub,39Uga-pub43), in private drug shops only (Uga-priv41),
and in a combination of public facilities, private pharmacies,
and drug shops (Nige-mix42). Most studies included were cluster
randomised trials of interventions, with the exception of two
individually randomised trials (Afgh-pub,36 Ghan-pub38), and
one descriptive study before and after national implementation
of rapid diagnostic tests (Tanz1-pub40). Table 2⇓ summarises
the intervention in each study.
Microscopy services were not present or were limited in five
study settings.36-43 In Cam-pub, microscopy was widely available
and its use increased during the time of the trial alongside a
national malaria campaign.37 In Tanz1-pub, microscopy was
available in some higher level facilities but was not frequently
used.40 The two individually randomised studies (Afgh-com (T
Leslie, et al, in preparation), Ghan-pub38) introduced rapid
diagnostic tests in some settings where routine care included
microscopy. In other countries, the effect of introducing tests
was evaluated against control settings where presumptive
clinical diagnosis was the norm.
Prescribing data were collected through patient exit interviews
or records of treatments administered (“registers”) completed
by the provider, both of these methods, and both registers and
follow-up interviews for a subset of patients (Uga-priv).41
The main outcome of interest was the proportion of patients in
each setting who were prescribed at least one systemic (oral or
injectable) antibiotic. Other outcomes included the type of
antibiotic prescribed.
Patient involvement
The development of the primary research studies, from which
these data are drawn, was informed by formative research among
health workers, community members, and other stakeholders
in the study settings; details for individual studies are available
in open access publications.44-47 Results of the individual trials
were disseminated to participants in their local contexts. Patients
were not directly involved in the design of the present analysis.
Analysis approach
We performed three analyses to represent different policy and
clinical perspectives. The main outcome for the first two
analyses is the risk ratio of being prescribed at least one systemic
(oral or injectable) antibiotic. The first analysis compared overall
antibiotic prescribing for each study, in settings with and without
rapid diagnostic test interventions; this represents the overall
policy effect of introducing diagnostic tests in a given context.
The second, restricted to patients in intervention settings, looked
at those with positive test result compared with those with
negative results. This analysis shows the effect of test result on
antibiotic prescribing. In the third analysis, we categorised
prescribed antibiotics by drug class to explore the range of
antibiotic classes used in different settings. We also examined
the impact of rapid diagnostic tests on prescription of the most
commonly used antibiotic classes, defined as those that were
prescribed to at least 5% of patients in at least one site, to see
if there was a differential effect of test result by antibiotic class.
To allow comparison of the impact of introduction of rapid
diagnostic tests for malaria and test results across studies, we
calculated the risk ratios with their 95% confidence intervals
for each study using binomial regression with a log link. The
Huber-White robust standard error was used to account for
correlation within the highest level of clustering (that is, within
randomisation clusters for the cluster randomised trials and
within study clinics for the individually randomised studies).48
We carried out a random effects meta-analysis including all
studies that compared groups randomised concurrently to
intervention or control—that is, excluding Tanz-1, which was
a before and after comparison, and Nige-mix and Tanz-2, which
compared groups randomised to interventions with
pre-intervention baseline data. For these three studies, table 3⇓
shows estimates of the impact of test introduction, but they do
not contribute to the formal meta-analysis.
Results
Table 1⇓ describes the study sites, including studies in
Afghanistan (two), Cameroon, Ghana, Nigeria, Tanzania (two),
and Uganda (two), and covering a range of epidemiological
settings. Data from the nine sites in six countries represent 522
480 patients with febrile illness or other malaria-like
presentations.
Of patients in intervention settings for whom a malaria test
result (slide or rapid diagnostic test) was available, 61 324/157
345 (39.0%) tested negative for malaria, ranging from 30.5%
(35 711/117 070 in southeast Uganda) to 99.8% (462/463 in
northern Afghanistan). Parasite prevalence acts as a proxy for
local endemicity.
Table 3⇓ shows overall data on diagnostic testing and antibiotic
prescribing for each study setting. In intervention settings, the
proportion of patients for whom a test was performed varied
from 23.1% (1137/4922) to 99.8% (724/733). The heterogeneity
of uptake of rapid test results is important to the generalisability
of these data to different settings.
Antibiotic prescription in settings with and
without interventions of rapid diagnostic tests
for malaria
Antibiotics were prescribed to 127 052/238 797 (53%) patients
in control groups and 167 714/283 683 (59%) in intervention
groups. The proportion of patients prescribed at least one
systemic (oral or injectable) antibiotic ranged from 18.2%
(110/605) to 72.8% (287/394) in control settings and from 15.2%
(752/4946) to 78.5% (1130/1439) in settings with a rapid test
intervention. Relative to control settings, the proportion of
patients receiving an antibiotic prescription was higher or had
a trend towards being higher where rapid diagnostic tests were
introduced in all but one of the studies (in Nigeria), with risk
ratios ranging from 0.65 to 2.98 (fig 1⇓, and table 3⇓). This
represents the overall impact on health systems of introducing
rapid diagnostic tests. A meta-analysis combining the
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randomised comparisons gave an overall risk ratio of 1.21 (95%
confidence interval 1.07 to 1.36; P=0.004)—that is, the risk of
antibiotic prescription was 21% higher where rapid diagnostic
tests were introduced, although there was an important
heterogeneity between studies (I2=65%).
Antibiotic prescription according to malaria
test results
In intervention settings across all studies, antibiotic prescribing
was higher among patients with negative malaria test results
than among patients with positive results (fig 2⇓ and table 4⇓).
Antibiotics were prescribed to 40% (35 505/89 719) of patients
with a positive test result and to 69% (39 400/57 080) of those
with a negative result. Differences were substantial in several
studies (Afgh-com/a, Afgh-pub/a and b, Cam-pub/a and b,
Ghan-pub, Tanz1-pub/a and c, Tanz2-pub, Uga-pub and
Uga-priv), with risk ratios overall varying from 1.13 to 15.17.
This represents the impact of health workers obtaining a test
result negative for malaria.
Types of antibiotics prescribed
Table 5⇓ shows the percentage of patients at each site who were
prescribed each class of antibiotic. Figure 3⇓ shows the
percentage contribution of each antibiotic class to total antibiotic
prescribing at each site. Penicillins and
trimethoprim-sulfamethoxazole (TMP-SMX, or cotrimoxazole)
were the most commonly prescribed antibiotics, with
metronidazole the third most prescribed antibiotic at most sites.
In Cam-pub, Nige-mix, and Tanz1-pub the type of antibiotic
prescribed was not known in 52.1% (2075/3982), 10.7%
(708/6588), and 15.9% (548/3456) of cases, respectively,
because of the data collection approach or coding.
Compared with patients with positive malaria test results,
prescription of each of the four most common classes of
antibiotic (penicillins, TMP-SMX, tetracyclines, and
metronidazole) was higher for patients with negative test results
across most sites (table 6⇓). Risk ratios ranged from 1.70 to
28.2 for penicillins, 0.96 to 19.7 for TMP-SMX, 3.21 to 9.0 for
tetracyclines, and 1.24 to 3.37 for metronidazole.
Discussion
In this analysis of African and Asian studies including over half
a million children and adults with acute febrile illness, we found
that introduction of rapid diagnostic tests for malaria to reduce
unnecessary use of antimalarials—a beneficial public health
outcome—could drive up empirical use of antibiotics.
Antimicrobial drug resistance can result in prolonged illnesses,
higher mortality, and increased costs of treatment and is a major
global concern.7Unnecessary overuse of antimicrobials increases
drug pressure and contributes to the development and spread of
antimicrobial resistance. Acute febrile illness is one of the most
common presenting syndromes in tropical and subtropical
regions, and patient and prescriber beliefs and behaviours
regarding management of fever influence antimicrobial use.49 50
Several studies, including the component studies in our analysis,
have shown that rapid diagnostic tests for malaria, when
combined with effective training, can reduce overuse of
antimalarials.8 Our current study, however, has shown that the
desired reduction in empirical use of antimalarial drugs was
often accompanied by an unintended shift toward increased
prescription of other antimicrobials, specifically antibiotics.
This shift was observed for multiple classes of antibiotics and
across several epidemiological and healthcare contexts where
rapid diagnostic tests were introduced. In particular, empirical
antibiotic use wasmuchmore common for patients with negative
malaria test results. These findings suggest that without
additional interventions, current major initiatives to introduce
rapid diagnostic tests for malaria—which could effectively
reduce inappropriate use of antimalarials and the risk of
antimalarial drug resistance14—can unintentionally exchange
presumptive overuse of antimalarials for presumptive overuse
of antibiotics. The potential for this prescribing shift was
recognised in the early days of increasing the use of these tests,16
and these concerns now seem to be real in many settings.18 There
is a widespread assumption that improving pathogen specific
diagnosis with better tests will reduce overuse of antimicrobials,
but it might simply shift overuse from one class to another.
Strengths and weaknesses of study
The strengths of the study include the wide range of
geographical, epidemiological, and healthcare settings that are
typical of contexts where rapid diagnostic tests for malaria will
be used and the consistency and size of the effect on antibiotic
prescribing. Data from over 520 000 patient encounters in Africa
andAsia were available, providing the broadest sample currently
available to evaluate shifts in prescribing behaviour associated
with test implementation.
As with all studies there are limitations. The ACT Consortium
studies were conducted in sites representative of where most
patients typically seek treatment. As advanced microbiology
diagnostic facilities were not readily available at these sites, the
data do not allow determination of whether antibiotic use was
appropriate for individual patients. Antibiotic availability varied
across study settings, which increases generalisability of the
results but also means that sites are not strictly comparable in
terms of drugs or classes used. Limitations of individual studies
are reported in the published papers on their findings.
This analysis design can robustly identify that there is an
increase in antibiotic prescribing after introduction of rapid
diagnostic tests for malaria, but it cannot identify the reasons
for this shift at an individual prescriber level. Qualitative
research would be better suited to answer such questions.
Combination of data from studies with meta-analysis must be
undertaken with caution when the data come from highly
variable epidemiological settings and different health settings.
We therefore consider the summary statistic useful, but it should
not be overinterpreted, and the consistency of results across
different settings is equally important.
There were no major outbreaks (such as the Ebola epidemic in
West Africa) in any of the study sites that might have affected
the results.
Interpretation in light of other studies
It is not possible to know whether antibiotic prescription was
appropriate at the individual patient level in this analysis because
the studies did not collect full clinical data or samples for further
laboratory investigation. In most similar settings where bacterial
diagnosis has been undertaken, however, few patients have
documented bacterial infections; fewer than 2% (and in virtually
all reports <5%) of patients with uncomplicated febrile illness
have positive results on blood cultures.51-53 Not all bacterial
causes of fever lead to bacteraemia, but, for example, in young
children with uncomplicated febrile illness in Zanzibar, just
22% had an infection retrospectively considered to require
antibiotics.54 At a population level it is likely that relatively few
patients in our studies had bacterial infections requiring
antibiotic treatment, and the incidence is unlikely to be anywhere
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near the 69% suggested by antibiotic prescription to those with
negative results of malaria tests.
Case management guidelines for limited resource settings, such
as the WHO’s Integrated Management of Childhood Illness
(IMCI) and Integrated Management of Adult and Adolescent
Illness, do not recommend empirical use of antibiotics for
non-severe febrile illness of unclear aetiology.55 56 The extent
to which these guidelines are used, or adhered to, however,
varies by setting. Studies in settings where antibiotics are not
available to prescribers, such as chemist shops in Ghana, have
shown that withholding both antibiotics and antimalarials diverts
patients to antipyretics, which is a safe strategy for most
uncomplicated illness.57
With declining incidence of malaria in many settings, the
proportion of fevers attributable to illnesses other than malaria
stands to increase. Currently rapid diagnostic tests are more
useful to rule out malaria than to rule it in, at least in Africa,
but this is likely to change as the incidence of malaria drops.
As this transition occurs and the proportion of negative test
results increases, the risk of inappropriate antibiotic treatment
of patients with negative results is likely to increase as well.
Widespread childhood vaccination for pneumococcus,
meningococcus, and Haemophilus influenzae type B, and the
resulting reduction in bacteraemia and bacterial infection, have
further reduced the risk that non-specific, non-severe febrile
illness is caused by a potentially serious bacterial pathogen in
many African and Asian countries.58-60
Even when treatment with antibiotics is warranted, patients
might not receive the most appropriate antibiotic for their illness,
particularly in settings with inadequate healthcare
infrastructure.20 In the studies we analysed, choice of
antibacterial was inevitably untargeted as health workers in
these settings do not have access to facilities to confirm
diagnoses and identify pathogens nor to epidemiological data
to help guide antibiotic choices—a health systemweakness that
is unfortunately typical across most malaria endemic areas. In
the ACT Consortium studies, nearly all antibiotic prescriptions
were for penicillins, trimethoprim-sulfamethoxazole,
tetracyclines, and, in several sites, metronidazole. The fact that
metronidazole prescribing was more common where rapid
diagnostic tests for malaria were introduced, similar to the
pattern for other antibiotic classes, suggests a relatively
haphazard approach to empirical prescribing; few causes of
malaria-like febrile illness can be effectively treated with
metronidazole.
Within each study site, different antibiotics predominated, which
could reflect to varying degrees local availability including
stockouts (when healthcare facilities run out) of antibiotics
because of intermittent supply,61 recommendations in national
or other clinical guidelines such as IMCI,56 and personal or
institutional preferences. Other broad spectrum antibiotics such
as cephalosporins, fluoroquinolones, and macrolides were
relatively infrequently prescribed in the sites studied and are
probably either less available or affordable or are thought to be
restricted to particular indications; this could change over the
next few years. Of note, at most sites tetracyclines accounted
for only a tiny fraction of antibiotics prescribed, even among
non-paediatric patients; yet this inexpensive antibiotic class
could be a rational empirical choice to cover zoonotic infectious
agents such as rickettsiae, leptospira, and several bacteria that
cause a considerable proportion of infections in these areas.17-64
Reliable data on antibiotic resistance are scarce to non-existent
in regions typified by ACT Consortium study sites20; reports
that are available from Africa indicate that, for example,
currently 1% to 100% of Streptococcus pneumoniae isolates
are resistance to penicillin, while 0% to 35% isolates of
non-typhoidal salmonella are resistant to fluoroquinolones.65
Clinical casemanagement typically follows an expected pathway
that culminates in the prescription or purchase of medicines.66 67
In low resource settings, antimicrobial medicines are often the
cornerstone of care.68 69 Presentation of fever is expected to
result in antimicrobial prescription.49-71 Behaviour change to
reduce unnecessary overuse of antimalarials can occur when
introduction of diagnostic technologies is accompanied by a
well designed and implemented programme of training and
supervision.37-41
Meaning of study for policy and clinical
practice
This analysis suggests that while introduction of rapid diagnostic
tests for malaria can reduce untargeted excessive use of
antimalarials—a highly beneficial public health outcome across
malaria endemic regions—it can also have the unintended
consequence of driving up untargeted and probably excessive
use of antibiotics. In this analysis, the shift included antibiotics
from several classes and was consistent across nearly all the
varied clinical and epidemiological settings studied, increasing
the generalisability of the findings. Therefore when rapid
diagnostic tests are introduced, policymakers and clinicians
should avoid a switch to overuse of antibiotics, a concern that
increases the challenges of changing prescribing practice. This
awareness is important in the design of programmes for provider
training and community education in Africa and Asia, where
antibiotic use is already relatively unregulated and
unrestricted.20-65 Without thoughtful intervention in the near
term, as the burden of malaria declines and negative malaria
test results become more common, the trend toward
compensatory prescription of antibiotics can only contribute to
increasing levels of antibiotic resistance.
Unanswered questions and future research
This analysis shows quantitatively that introduction of rapid
diagnostic tests for malaria can lead to an increase in antibiotic
prescribing in many settings. Two major gaps in evidence need
to be filled to inform policy and clinical practice guidelines to
deal with this problem. The first is to identify the current drivers
of this prescribing behaviour (mainly with qualitative research
but also with epidemiology) to inform efforts toward behaviour
change. The second, especially important for the rational
revision of diagnostic algorithms such as IMCI, is to identify
the treatable or preventable causes of non-malaria febrile illness
(mainly with microbiology, virology, and epidemiology).
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What is already known on this topic
Antimalarial drugs are widely overprescribed: introduction of rapid diagnostic tests for malaria reduces overprescription and helps target
antimalarial drugs to those who need them
Antibiotics are also widely overprescribed, and antimicrobial resistance poses a fundamental threat to human health, development, and
security
What this study adds
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This effect is seen across multiple settings in Africa and Asia and, in large part, probably represents increased overprescribing of
antibiotics
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Tables
Table 1| Description of study contexts and populations of patients according to whether they underwent rapid diagnostic test for malaria
(mRDT)
Study dates
Median (IQR)
patient age
(years)
Healthcare
sectorSetting
Percentage (No) of
positive test results
in symptomatic
patients*
No of patient encounters
Region and study
abbreviation mRDTControl
Oct 2011-May
2012
14 (8-30)CommunityUrban and rural28.8 (208/723)733607East Afghanistan
(Afgh-com/a)
(1/463)466594North Afghanistan
(Afgh-com/b)
Sept 2009-Sept
2010
13 (7-25)PublicUrban and rural27.1 (555/2048)20482005East Afghanistan
(Afgh-pub/a)
(7/856)856840North Afghanistan
(Afgh-pub/b)
Oct-Dec 201113 (3-29)Public/missionUrban and rural18.4 (202/1098)1477400West Cameroon (Cam-pub/a)
50.6 (715/1412)1824281Central Cameroon
(Cam-pub/b)
Aug 2007-Dec 200813 (4-32)PublicRural36.0 (1308/3629)36293634South east Ghana
(Ghan-pub)
May-Oct 2010;
April-July 2012†
2 (1-17)PublicRural/peri-urban21.4 (77/360)750689North Tanzania
(Tanz1-pub/a)
10.8 (18/167)388559West Tanzania (Tanz1-pub/b)
46.9 (192/409)572498South east Tanzania
(Tanz1-pub/c)
Sept 2010-Jan
2011; Feb
2011-March 2012†
11 (2-31)PublicRural25.4 (4400/17 297)44 12116 068North east Tanzania
(Tanz2-pub)
April 2011-March
2013
12 (3-28)PublicRural69.5 (81 359/117 070)221 755210 758South east Uganda
(Uga-pub)
Jan–Dec 20118 (2 – 22)Private retailRural57.0 (5690/9987)10 365‡8109‡South central Uganda
(Uga-priv)
July–Dec 2009;
June-Dec 2011†
26 (18 – 35)Public and
private retail
Urban and rural52.3 (589/1126)49461642South central Nigeria
(Nige-mix)
IQR=interquartile range.
*Proportion of patients testing positive for malaria (among those in intervention settings who were tested) presented as proxy for malaria epidemiology.
†Ranges separated by semicolon indicate pre-/post- evaluations conducted before and after introduction of mRDTs. Other studies consisted of multiple study
arms without (control) and with (intervention) mRDTs, evaluated simultaneously.
‡In Uga-priv only a subset of patients (n=497; 248 in control setting, 249 in intervention setting) were followed up after consultation to collect data on medicines
prescribed.
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Table 2| Description of study designs and interventions in patients who underwent rapid diagnostic test for malaria (mRDT)
Training† provided with test introduction in intervention
settingsTests used*DesignStudy abbreviation
One day MoH training: performing mRDTs and prescribing
antimalarials
CareStart Pf/Pan, AccessBioCluster randomised trialAfgh-com
One day MoH training: performing mRDTs and prescribing
antimalarials
CareStart Pf/Pan, AccessBioIndividually randomised trialAfgh-pub
One day training: performing mRDTs, prescribing antimalarials.
Enhanced training group: additional two day interactive training
on adapting to the malaria guideline change including identifying
major alternative causes of febrile illness, and communication
skills
SD Bioline Malaria Ag Pf/Pan,
Standard Diagnostics
Cluster randomised trialCam-pub
Two day training: use of mRDTs, antimalarial prescribing,
identifying major alternative causes of febrile illness
OptiMAL-IT, Diamed AGIndividually randomised trialGhan-pub
Two day MoH training: performing mRDTs, prescribing
antimalarials, rationale for malaria guideline change, identifying
major alternative causes of febrile illness
Primarily SD Bioline Pf, Standard
Diagnostics
Baseline and follow-up surveys
before and after mRDT
introduction
Tanz1-pub
Two day MoH training: performing mRDTs, prescribing
antimalarials, rationale for malaria guideline change, identifying
major alternative causes of febrile illness. Enhanced training
group: three additional half day workshops on adapting to and
sustaining guideline change, and communication skills
Paracheck Pf, Orchid Biomedical
Systems
Baseline survey followed by
cluster randomised trial
Tanz2-pub
Two day training plus on site supervision: performing mRDTs,
prescribing antimalarials, identifying major alternative causes of
febrile illness, and communication skills
Primarily SD Bioline Pf, or SD Bioline
Pf/Pan, Standard Diagnostics
Cluster randomised trialUga-pub
Four day training: performing mRDTs, prescribing antimalarials,
referral algorithm for mRDT-negative results, and communication
skills
First Response Ag Pf card, Premier
Medical Corporation
Cluster randomised trialUga-priv
Half day training: demonstration onmRDT use. Enhanced training
group: additional two day training on performing mRDTs,
prescribing antimalarials, and communication skills
SD Bioline Malaria Ag Pf/Pan,
Standard Diagnostics
Formative study followed by
cluster randomised trial
Nige-mix
MoH=Ministry of Health.
*mRDTs selected in agreement with national health authorities and supplied by studies in most cases, except in Tanz1-pub where they were supplied by MoH as
part of national scale-up, and in Uga-pub where they were supplied by MoH with study back-up in case of stockouts of antibiotics because of intermittent supply.
†Many training programmes included information on identifying alternative causes of fever; none included systematic guidance on management of alternative
causes of fever.
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Table 3| Malaria diagnostic testing, test results, and antibiotic prescribing in control areas compared with areas where rapid diagnostic
tests for malaria (mRDTs) were introduced
Risk ratio for
antibiotic
Percentage (No) prescribed at
least one antibiotic
Percentage (No) of those tested
whose result was negative
Percentage (No) who underwent
diagnostic test
Study
prescription in
mRDT area v
control area
(95% CI)
mRDTControl*mRDTControl*mRDTControl*
2.98 (1.62 to 5.5)54.1 (383/708)18.2 (110/605)71.2 (515/723)0†98.8 (724/733)0 (0)Afgh-com/a
1.41 (0.93 to 2.15)68.5 (317/463)48.4 (286/591)99.8 (462/463)0†100 (466/466)0 (0)Afgh-com/b
1.07 (0.99 to 1.17)
40.8 (836/2048)38.1 (763/2005)72.9 (1493/2048)67.9
(1357/2000)
100‡ (2048/2048)100‡
(2005/2005)
Afgh-pub/a
1.39 (0.99 to 1.97)70.6 (604/856)50.6 (425/840)99.2 (849/856)96.6 (450/466)100‡ (856/856)55.5‡ (466/840)Afgh-pub/b
1.08 (0.93 to 1.26)78.5 (1130/1439)72.8 (287/394)81.6 (896/1098)75.6 (232/307)75.3 (1111/1475)78.3 (313/400)Cam-pub/a
1.03 (0.66 to 1.63)52.1 (925/1774)50.4 (140/278)49.4 (697/1412)6.0 (13/218)79.5 (1448/1822)80.4 (226/281)Cam-pub/b
1.10 (0.97 to 1.24)
32.3 (1168/3615)29.5 (1069/3623)64.0 (2321/3629)69.7
(1320/1907)
100‡ (3629/3629)52.5‡
(1908/3634)
Ghan-pub
1.51 (1.12 to 2.03)44.7 (335/749)29.7 (204/688)78.6 (283/360)50.0 (25/50)48.4 (363/750)7.3 (50/689)Tanz1-pub/a§
1.60 (1.27 to 2.02)56.4 (219/388)35.2 (197/559)89.2 (149/167)50.7 (36/71)43.2 (167/387)12.7 (71/559)Tanz1-pub/b§
1.48 (1.19 to 1.84)49.0 (280/572)33.1 (165/498)53.1 (217/409)44.9 (70/156)71.5 (409/572)31.3 (156/498)Tanz1-pub/c§
1.19 (1.13 to 1.25)
73.2 (32 274/44
121)
61.5 (9875/16
068)
74.6 (12 897/17
297)
0†39.8¶ (17 559/44
119)
0 (0/16 068)Tanz2-pub
1.08 (0.90 to 1.30)
57.9 (128
404/221 755)
53.7 (113 101/
210 758)
30.5 (35 711/117
070)
41.3 (6261/15
171)
52.9 (117
350/210 578)
7.3 (15 285/210
758)
Uga-pub
1.80 (1.30 to 2.50)
34.9 (87/249)**19.4 (48/248)**43.0 (4297/9987)0†97.3 (10 078/10
365)
0 (0/8109)Uga-priv
0.65 (0.46 to 0.93)15.2 (752/4946)23.3 (382/1642)47.7 (537/1126)0 (0/25)23.1 (1137/4922)1.7 (27/1634)Nige-mix
*Microscopy services were not present or were limited in five study settings. In Cam-pub, microscopy was widely available and its use increased during the time
of the trial alongside a national malaria campaign. In Tanz1-pub, microscopy was available in some higher level facilities but was not frequently used. The two
individually randomised studies (Afgh-com, Ghan-pub) introduced rapid diagnostic tests in some settings where routine care included microscopy. In other countries,
the effect of introducing tests was evaluated against control settings where presumptive clinical diagnosis was the norm.”
†No observations (no testing available or performed in control area).
‡Afgh-pub and Ghan-pub were individually randomised trials; all patients in intervention group were tested with malaria rapid diagnostic test (mRDT); in control
group, half were tested by microscopy, and half were diagnosed clinically.
§Tanz1 recorded medicines actually obtained by patients; other studies recorded medicines prescribed.
¶Figure is lower than that reported in primary paper39 because the present analysis included all patients with data, rather than only patients defined by study as
mRDT-eligible.
**Only subset of patients (n=497) in Uga-priv followed up after consultation to collect data on medicines prescribed.
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Table 4| Antibiotic prescribing by test result in areas with rapid diagnostic test for malaria (mRDT) intervention
Risk ratio for antibiotic prescription for test
negative v test positive patients (95% CI)
Percentage (No) of patients prescribed at least one antibiotic*Study
Positive test resultNegative test result
9.0 (6.2 to 12.9)8.1 (16/197)72.8 (366/503)Afgh-com/a
—†0 (0/1)68.9 (316/459)Afgh-com/b
15.2 (8.0 to 28.9)3.6 (20/555)54.7 (816/1493)Afgh-pub/a
5.0 (2.31 to 10.7)14.3 (1/7)71.0 (603/849)Afgh-pub/b
1.13 (1.00 to 1.26)72.5 (140/193)81.6 (718/880)Cam-pub/a
1.15 (0.96 to 1.37)50.9 (356/700)58.5 (397/679)Cam-pub/b
2.50 (2.16 to 2.91)16.5 (215/1305)41.3 (953/2310)Ghan-pub
1.68 (1.00 to 2.83)31.6 (24/76)53.0 (150/283)Tanz1-pub/a‡
1.31 (0.57 to 3.04)44.4 (8/18)58.4 (87/149)Tanz1-pub/b‡
2.01 (1.42 to 2.85)30.7 (59/192)61.8 (134/217)Tanz1-pub/c‡
2.51 (2.04 to 3.09)30.1 (1326/4400)75.6 (9750/12 897)Tanz2-pub
1.71 (1.38 to 2.12)40.8 (33 214/81 359)69.9 (24 963/35 711)Uga-pub
1.95 (1.41 to 2.69)23.6 (30/127)46.0 (52/113)Uga-priv
1.09 (0.79 to 1.49)16.3 (96/589)17.7 (95/537)Nige-mix
*Where denominators do not sum to total, uptake of mRDTs by clinicians was not 100%, so that mRDT not performed for proportion of patients seen.
†Comparison not possible where no mRDT-positive patients received antibiotic.
‡Tanz1 recorded drugs actually obtained by patients; other studies recorded medicines prescribed.
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Table 5| Proportion (number) of all patients seen who were prescribed each class of antibiotics*
Type
unknown
OtherMetronidazoleAmino-glycoside
(gentamicin)
ChloramphenicolQuinoloneTMP/SMXTetracyclineMacrolideCephalo-sporinPenicillin
1.1 (66)0.1
(4)
2.1 (122)0 (0)5.0 (289)0.2 (10)10.4 (598)0.9 (50)0.5 (30)0.1 (6)26.5
(1523)
Afgh-pub†
(n=5749)
52.1
(2075)
0.1
(3)
7.0 (277)0.5 (21)0.8 (31)1.3 (50)1.0 (39)0.5 (20)1.7 (66)2.0 (80)5.0 (200)Cam-pub
(n=3982)
0 (0)0.01
(1)
7.5 (544)0.01 (1)0.9 (62)2.8 (202)2.9 (213)0.5 (33)0.7 (54)1.7 (120)17.6
(1281)
Ghan-pub
(n=7263)
15.9 (548)0 (0)1.9 (66)0.03 (1)0.5 (17)0.1 (3)17.0 (588)0 (0)0.1 (4)0.03 (1)8.8 (304)Tanz1-pub‡
(n=3456)
0.1 (59)0 (0)5.1 (3056)0.01 (6)0.8 (499)1.4 (843)24.5 (14
766)
5.4 (3247)4.8 (2863)0.04 (22)31.5 (18
928)
Tanz2-pub
(n=60 189)
0 (0)0.1
(448)
6.9 (29 622)1.2 (5339)0.01 (45)1.6 (6776)32.8 (141
904)
1.5 (6421)0.6 (2586)0.02 (100)18.7 (80
748)
Uga-pub
(n=432
513)
0 (0)0 (0)4.6 (23)0 (0)2.2 (11)0.8 (4)9.3 (46)0.4 (2)3.6 (18)0.2 (1)9.3 (46)Uga-priv§
(n=497)
10.7 (708)0.02
(10)
1.7 (109)0 (0)0.4 (24)0.7 (48)2.0 (131)0.2 (11)0.4 (23)0.2 (14)2.3 (154)Nige-mix
(n=6588)
*Penicillins primarily included oral and injectable penicillin formulations, and amoxicillin with or without clavulanic acid, as well as ampicillin, cloxacillin, dicloxacillin, and
flucloxacillin; cephalosporins included first and second generation cephalosporins, as well as ceftriaxone and cefixime; macrolides included azithromycin and erythromycin;
tetracycline was typically doxycycline; TMP/SMX=trimethoprim-sulfamethoxazole; quinolones primarily included ciprofloxacin, as well as levofloxacin, nalidixic acid,
norfloxacin, and sparfloxacin; metronidazole also included secnidazole, tinidazole; “other” included clindamycin, nitrofurantoin, thalazole, and others.
†Data presented only for Afghanistan study in public health facilities (Afgh-pub/a and Afgh-pub/b). In study among community health workers in Afghanistan (Afgh-com/a
and Afgh-com/b) trimethoprim-sulfamethoxazole was only antibiotic available to prescribers.
‡Tanz1 recorded drugs actually obtained by patients; other studies recorded drugs prescribed.
§Only subset of patients (n=497) in Uga-priv were followed up after consultation to collect data on drugs prescribed.
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Table 6| Risk ratios (95% confidence interval) for antibacterial prescription by class* for patients with negative v test positive test results
in rapid diagnostic test for malaria (mRDT) intervention†
TetracyclineMetronidazoleTMP/SMXPenicillin
6.5 (0.97 to 43)0‡19.7 (7.2 to 54)28.2 (11.5 to 69)Afgh-pub
6.3 (0.86 to 46)1.24 (0.78 to 1.97)0.96 (0.47 to 1.94)1.70 (1.08 to 2.69)Cam-pub
9.0 (0.94 to 87)2.64 (1.55 to 4.5)3.57 (2.30 to 5.5)2.25 (1.72 to 2.95)Ghan-pub
0‡0‡1.32 (0.88 to 1.98)3.21 (1.80 to 5.7)Tanz1-pub§
3.21 (1.98 to 5.2)2.45 (1.38 to 4.3)1.87 (1.45 to 2.40)3.73 (2.82 to 4.9)Tanz2-pub
7.0 (4.7 to 10.5)3.37 (2.72 to 4.2)1.48 (1.13 to 1.95)2.17 (1.68 to 2.80)Uga-pub
0‡2.47 (0.76 to 8.0)1.43 (0.70 to 2.91)2.00 (0.98 to 4.1)Uga-priv
*Penicillins primarily included oral and injectable penicillin formulations, and amoxicillin with or without clavulanic acid, as well as ampicillin, cloxacillin, dicloxacillin,
and flucloxacillin; TMP/SMX=trimethoprim-sulfamethoxazole; metronidazole also included secnidazole, tinidazole; tetracycline was typically doxycycline.
†Afgh-com, study among community health workers in Afghanistan, dropped from this analysis because trimethoprim-sulfamethoxazole was only antibiotic to
which participating health workers had access. Nige-mix, study in Nigeria, dropped from this analysis as no or few observations in many relevant categories.
‡No or few observations in relevant categories.
§Tanz1 recorded drugs actually obtained by patients; other studies recorded medicines prescribed.
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Figures
Fig 1 Risk ratios for antibiotic prescription in randomised studies comparing patients in control settings with patients in
settings where malaria rapid diagnostic test intervention was implemented. Weights are from random effects analysis
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Fig 2 Risk ratios for antibiotic prescription in settings with malaria rapid diagnostic test intervention, comparing patients
with positive versus negative malaria test results. Afgh-com/b is not included because risk ratio could not be calculated;
comparison is not possible when no patients with positive test results received antibiotic
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Fig 3 Antibiotic class as proportion of all antibiotics prescribed in each study (control and intervention settings combined).
Afghanistan data are from Afgh-pub only; Afgh-com health workers had access only to trimethoprim-sulfamethoxazole.
White areas for Cameroon, Nigeria, Afghanistan, and Tanzania-1 indicate that systemic (oral or injectable) antibiotic was
prescribed but that name was not specified in study records. Labels indicate classes that accounted for ≥5% of all antibiotics
prescribed for each study
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